Target BCMA for RRMM

INDICATION

BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.1

The first and only BCMA-targeted antibody-drug conjugate (ADC) monotherapy1

Watch our latest videos below with key experts discussing the latest “hot topics” and their implications in patient care.

The evolving treatment landscape and unmet needs in relapsed/refractory multiple myeloma (RRMM)

Dr Karthik Ramasamy discusses the current standard of care in triple refractory multiple myeloma, and the rationale for targeting B-cell maturation antigen (BCMA)

BLENREP (belantamab mafodotin) in triple refractory RRMM: a clinical data review

Dr Rakesh Popat presents the DREAMM-2 study, including key efficacy results, safety data, and patient-reported outcomes data

Monitor, Minimise, Modify: the 3 Ms of corneal AE management

Miss Simona Degli Esposti and Dr Rakesh Popat discuss the practicalities of managing corneal adverse events across the MDT

Real-world patient case studies

Panel discussion and Q&A

Reference

  1. BLENREP (belantamab mafodotin) Summary of Product Characteristics

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

January 2022 | PM-GB-BLM-WCNT-210003 (V1.0)